XML 16 R5.htm IDEA: XBRL DOCUMENT v3.25.3
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Earnings (Loss)
Noncontrolling Interest (NCI)
Total
Beginning balance at Dec. 30, 2023 $ 61,621 $ 354,702 $ 2,582,332 $ 1,106 $ 30,429 $ 3,030,190
Increase (Decrease) in Stockholders' Equity            
Net earnings (loss)     120,791   622 121,413
Foreign currency translation adjustment       (1,419) 616 (803)
Unrealized gain (loss) on debt securities       6   6
Distributions to NCI         (3,331) (3,331)
Cash dividends     (20,411)     (20,411)
Issuance of shares under employee stock purchase plan 6 648       654
Issuance/net forfeitures of shares under stock grant programs 369 5,829       6,198
Issuance of shares under deferred compensation plans 77 (77)        
Repurchase of shares (319) (17,686) (18,631)     (36,636)
Expense associated with share-based compensation arrangements   11,194       11,194
Accrued expense under deferred compensation plans   7,621       7,621
Ending balance at Mar. 30, 2024 61,754 362,231 2,664,081 (307) 28,336 3,116,095
Increase (Decrease) in Stockholders' Equity            
Net earnings (loss)     125,930   652 126,582
Foreign currency translation adjustment       (5,594) (2,220) (7,814)
Unrealized gain (loss) on debt securities       (64)   (64)
Other   (607)       (607)
Distributions to NCI         (6,069) (6,069)
Cash dividends     (20,249)     (20,249)
Issuance of shares under employee stock purchase plan 9 807       816
Issuance/net forfeitures of shares under stock grant programs 29 1 5     35
Issuance of shares under deferred compensation plans 10 (10)        
Repurchase of shares (883)   (99,681)     (100,564)
Expense associated with share-based compensation arrangements   7,954       7,954
Accrued expense under deferred compensation plans   1,395       1,395
Ending balance at Jun. 29, 2024 60,919 371,771 2,670,086 (5,965) 20,699 3,117,510
Increase (Decrease) in Stockholders' Equity            
Net earnings (loss)     99,800   2,370 102,170
Foreign currency translation adjustment       1,029 (1,236) (207)
Unrealized gain (loss) on debt securities       550   550
Other   (390)       (390)
Distributions to NCI         (2,448) (2,448)
Purchase of remaining NCI of subsidiary   8,400       8,400
Cash dividends     (20,061)     (20,061)
Issuance of shares under employee stock purchase plan 6 646       652
Issuance/net forfeitures of shares under stock grant programs (10) 45 18     53
Issuance of shares under deferred compensation plans 8 (8)        
Repurchase of shares (198)   (21,562)     (21,760)
Expense associated with share-based compensation arrangements   8,021       8,021
Accrued expense under deferred compensation plans   1,329       1,329
Ending balance at Sep. 28, 2024 60,725 389,814 2,728,281 (4,386) 19,385 3,193,819
Beginning balance at Dec. 28, 2024 60,724 403,379 2,775,280 (15,311) 20,553 3,244,625
Increase (Decrease) in Stockholders' Equity            
Net earnings (loss)     78,753   853 79,606
Foreign currency translation adjustment       2,744 (31) 2,713
Unrealized gain (loss) on debt securities       470   470
Other   (355)       (355)
Cash dividends     (21,322)     (21,322)
Issuance of shares under employee stock purchase plan 7 643       650
Issuance/net forfeitures of shares under stock grant programs 232 3,055 101     3,388
Issuance of shares under deferred compensation plans 81 (81)        
Repurchase of shares (649) (9,460) (59,991)     (70,100)
Expense associated with share-based compensation arrangements   11,493       11,493
Accrued expense under deferred compensation plans   7,888       7,888
Ending balance at Mar. 29, 2025 60,395 416,562 2,772,821 (12,097) 21,375 3,259,056
Increase (Decrease) in Stockholders' Equity            
Net earnings (loss)     100,734   376 101,110
Foreign currency translation adjustment       10,239 1,615 11,854
Unrealized gain (loss) on debt securities       (118)   (118)
Other   (1,818)       (1,818)
Distributions to NCI         (285) (285)
Cash dividends     (20,656)     (20,656)
Issuance of shares under employee stock purchase plan 8 636       644
Issuance/net forfeitures of shares under stock grant programs 27 17 1     45
Issuance of shares under deferred compensation plans 10 (10)        
Repurchase of shares (1,874) (13) (189,506)     (191,393)
Expense associated with share-based compensation arrangements   8,755       8,755
Accrued expense under deferred compensation plans   1,269       1,269
Ending balance at Jun. 28, 2025 58,566 425,398 2,663,394 (1,976) 23,081 3,168,463
Increase (Decrease) in Stockholders' Equity            
Net earnings (loss)     75,346   253 75,599
Foreign currency translation adjustment       (354) 471 117
Unrealized gain (loss) on debt securities       570   570
Other   (177)       (177)
Distributions to NCI         (995) (995)
Cash dividends     (20,512)     (20,512)
Issuance of shares under employee stock purchase plan 7 565       572
Issuance/net forfeitures of shares under stock grant programs (30) 37 37     44
Issuance of shares under deferred compensation plans 11 (11)        
Repurchase of shares (297) (22) (28,758)     (29,077)
Expense associated with share-based compensation arrangements   7,497       7,497
Accrued expense under deferred compensation plans   1,154       1,154
Ending balance at Sep. 27, 2025 $ 58,257 $ 434,441 $ 2,689,507 $ (1,760) $ 22,810 $ 3,203,255